What's Going On With Leukemia-Focused Syndax Pharmaceuticals Stock Today?
Portfolio Pulse from Vandana Singh
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) stock rose after positive trial results for revumenib in acute leukemias were presented at the ASH Annual Meeting. The AML trial showed a 100% response rate, with 67% achieving MRD negative status. Data from the BEAT AML and AUGMENT-102 trials also showed high rates of CR/CRh and MRD negative status, with several patients proceeding to transplant. SNDX shares increased by 8.9% to $18.14.
December 11, 2023 | 6:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Syndax Pharmaceuticals' stock is trading higher due to positive results from trials of revumenib for acute leukemias, with high response rates and MRD negative status in patients.
The positive trial results are significant for Syndax Pharmaceuticals as they demonstrate the potential efficacy of revumenib, which could lead to increased investor confidence and demand for SNDX shares. The data presented at a major medical conference adds credibility and visibility to the findings, likely contributing to the stock's rise.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100